5-(2-Aminoethyl)pyrrolidin-2-one hydrochloride | 1803570-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 5-(2-Aminoethyl)pyrrolidin-2-one hydrochloride
• 英文别名: 5-(2-aminoethyl)pyrrolidin-2-one;hydrochloride
• CAS: 1803570-39-9
• 化学式: C6H13ClN2O
• mdl: MFCD28383935
• 分子量: 164.63
• InChiKey: HKOLXKWRLHOHLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.26
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.1
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES<br/>[FR] COMPOSÉS TRIARYLES POUR LE TRAITEMENT DE MALADIES PD-L1
  申请人：CHEMOCENTRYX INC

  公开号：WO2020232256A1

  公开（公告）日：2020-11-19

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  提供了一些作为免疫调节剂有用的化合物。这些化合物具有公式（I），包括立体异构体和其药用盐，其中R1a、R1b、R1c、R1d、R2a、R2b、R3、R3a、R4、R6、R7、R8、A、Z、X1和n如本文所定义。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• Triaryl compounds for treatment of PD-L1 diseases
  申请人：CHEMOCENTRYX, INC.

  公开号：US11266643B2

  公开（公告）日：2022-03-08

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本研究提供了可用作免疫调节剂的化合物。这些化合物具有式（I） 其中 R1a、R1b、R1c、R1d、R2a、R2b、R3、R3a、R4、R6、R7、R8、A、Z、X1 和 n 如本文所定义。还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。
• TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES
  申请人：CHEMOCENTRYX, INC.

  公开号：US20200383979A1

  公开（公告）日：2020-12-10

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 3 , R 3a , R 4 , R 6 , R 7 , R 8 , A, Z, X 1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.